[{"NetIncomeLoss_1_Q3_USD":-30743000.0,"ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_3_Q3_USD":2156000.0,"GeneralAndAdministrativeExpense_3_Q3_USD":28290000.0,"GeneralAndAdministrativeExpense_1_Q3_USD":11663000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3_Q3_shares":14942213.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q3_shares":15704293.0,"AccruedLiabilitiesCurrent_0_Q3_USD":16817000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q3_USD":2143000.0,"NetCashProvidedByUsedInInvestingActivities_3_Q3_USD":-78000.0,"StockIssuedDuringPeriodValueNewIssues_1_Q3_USD":150400000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3_Q3_shares":747025.0,"AssetsCurrent_0_Q3_USD":286890000.0,"CommonStockSharesIssued_0_Q3_shares":19073498.0,"Assets_0_Q3_USD":311102000.0,"OtherComprehensiveIncomeLossNetOfTax_3_Q3_USD":-4309000.0,"OtherComprehensiveIncomeLossNetOfTax_1_Q3_USD":-4031000.0,"Liabilities_0_Q3_USD":99342000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q3_USD":278691000.0,"OtherAssetsNoncurrent_0_Q3_USD":6401000.0,"IncreaseDecreaseInAccountsPayable_3_Q3_USD":-1221000.0,"IncreaseDecreaseInOtherNoncurrentAssets_3_Q3_USD":-425000.0,"ResearchAndDevelopmentExpense_3_Q3_USD":56727000.0,"ResearchAndDevelopmentExpense_1_Q3_USD":22200000.0,"IncreaseDecreaseInPrepaidExpense_3_Q3_USD":-1770000.0,"EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_Q3_USD":-66000.0,"IncreaseDecreaseInAccruedLiabilities_3_Q3_USD":-3213000.0,"IncomeTaxExpenseBenefit_3_Q3_USD":0.0,"ShareBasedCompensation_3_Q3_USD":10073000.0,"CommonStockValue_0_Q3_USD":190000.0,"StockIssuedDuringPeriodValueShareBasedCompensationGross_1_Q3_USD":5089000.0,"DepreciationDepletionAndAmortization_3_Q3_USD":119000.0,"ForeignCurrencyTransactionGainLossBeforeTax_3_Q3_USD":3968000.0,"NetCashProvidedByUsedInFinancingActivities_3_Q3_USD":219826000.0,"ProceedsFromNotesPayable_3_Q3_USD":9521000.0,"ComprehensiveIncomeNetOfTax_3_Q3_USD":-87143000.0,"ComprehensiveIncomeNetOfTax_1_Q3_USD":-34774000.0,"LongTermNotesPayable_0_Q3_USD":9508000.0,"ProceedsFromIssuanceOfCommonStock_3_Q3_USD":193399000.0,"CommonStockParOrStatedValuePerShare_0_Q3_USD":0.01,"CommonStockSharesAuthorized_0_Q3_shares":30000000.0,"AmortizationOfFinancingCostsAndDiscounts_3_Q3_USD":135000.0,"RetainedEarningsAccumulatedDeficit_0_Q3_USD":-242021000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3_Q3_USD":146848000.0,"CommonStockSharesOutstanding_0_Q3_shares":19073498.0,"Goodwill_0_Q3_USD":17260000.0,"InterestIncomeExpenseNet_3_Q3_USD":-7965000.0,"InterestIncomeExpenseNet_1_Q3_USD":-3639000.0,"IncreaseDecreaseInOtherOperatingLiabilities_3_Q3_USD":-1790000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_3_Q3_USD":-4309000.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":-72834000.0,"LiabilitiesCurrent_0_Q3_USD":21228000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q3_USD":278691000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q3_USD":8199000.0,"AdditionalPaidInCapital_0_Q3_USD":451448000.0,"PropertyPlantAndEquipmentNet_0_Q3_USD":551000.0,"NetIncomeLoss_3_Q3_USD":-82834000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1_Q3_USD":-4031000.0,"OtherOperatingIncomeExpenseNet_1_Q3_USD":4628000.0,"AccretionExpense_3_Q3_USD":7670000.0,"StockholdersEquity_0_Q3_USD":211760000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_3_Q3_USD":5592000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q3_USD":2131000.0,"OperatingIncomeLoss_3_Q3_USD":-74869000.0,"OperatingIncomeLoss_1_Q3_USD":-27104000.0,"AccountsPayableTradeCurrent_0_Q3_USD":3601000.0,"ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3_Q3_USD":24.78,"LiabilitiesAndStockholdersEquity_0_Q3_USD":311102000.0,"PaymentsToAcquirePropertyPlantAndEquipment_3_Q3_USD":78000.0,"AllocatedShareBasedCompensationExpense_3_Q3_USD":10073000.0,"OperatingExpenses_3_Q3_USD":80461000.0,"OperatingExpenses_1_Q3_USD":29235000.0,"EarningsPerShareBasicAndDiluted_3_Q3_USD":-5.54,"EarningsPerShareBasicAndDiluted_1_Q3_USD":-1.96,"ProfitLoss_3_Q3_USD":-82834000.0,"OtherLiabilitiesNoncurrent_0_Q3_USD":3735000.0,"OtherLiabilitiesCurrent_0_Q3_USD":810000.0,"AllocatedShareBasedCompensationExpense_1_Q3_USD":5089000.0,"OtherOperatingIncomeExpenseNet_3_Q3_USD":4556000.0,"Ticker":"ALBO","CIK":"1322505","name":"ALBIREO PHARMA, INC.","OfficialName":"Albireo Pharma Inc. Common Stock","form":"10-Q","period":"20200930","fy":"2020.0","fp":"Q3","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"688702712.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20201105"}]